Overcoming Hurdles for Soon-To-Be Practitioners, The Rising Chief Resident Summit - Tom Stringer

Tom Stringer joins Neal Shore to share highlights of his presentation at the first Rising Chief Residents Summit put together by the Large Urology Group Practice Association. This summit aims to support post-graduate year 4 and 5 residents during their transition to full-time practice. Dr. Stringer presented on crucial topics including vetting employment contracts, pursuing a career in academia, h...

Supporting Improved Patient Care Through Advanced Prostate Cancer Clinics - Gordon Brown

Neal Shore and Gordon Brown discuss the advanced prostate cancer clinics in large urology group practices (LUGPA). Gordon provides insight into supporting patient care within the urology practice as they scale the advanced prostate cancer clinic into a GU oncology care model. The advanced prostate cancer clinic is a clinical pathway and guidelines driven with physician champions using the NCCN and...

BCG Shortage 2019: Managing Through Treatment and Reimbursement Issues - Neal Shore, Ashish Kamat, and Jonathan Rubenstein

Neal Shore discusses the current 2019 shortage of BCG with Ashish Kamat and Jonathan Rubenstein. Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non–muscle-invasive bladder cancer. Bacille Calmette-Guérin (BCG) has been a standard of care for many patients with non-muscle invasive bladder cancer for decades.Merck & Co., Inc., has advised that...

ProVent Trial for Newly Diagnosed Prostate Cancer - Benjamin Lowentritt

Benjamin Lowentritt and Alicia Morgans discuss the ProVent trial, the use of sipuleucel-T in newly diagnosed prostate cancer patients on active surveillance. They discuss inclusion criteria, trial design and primary outcome measures which include assessing the efficacy of sipuleucel-T in reducing reclassification to a higher Gleason grade in patients on active surveillance. Biographies: Alicia Mor...

Evolution of Technology and Technique in Bladder Cancer - Ashish Kamat

(Length of Discussion: 10 min) Ashish Kamat and Alicia Morgans discuss the highlights of his presentation at LUGPA 2018, on the evolution of technology and technique when treating bladder cancer. The initial resection of the bladder is paramount to the path of management for these patients, including the type of anesthesia, angles of scopes, white light and blue light detection, narrow-band imagin...

Focal Therapy: Ready or Not - Herbert Lepor

(Length of Discussion: 20 min) Herb Lepor presents the current optimal management of localized prostate cancer including an in-depth review of focal ablation. He highlights technique, criteria for appropriate patient selection, and the value of counseling to managing expectations. Biography: Herbert Lepor, MD, Professor, Department of Urology, Professor, Department of Biochemistry and Molecular Ph...

Minimally Invasive Approaches in the Treatment of BPH: Ready to Replace TURP? - Claus Roehrborn

Claus Roehrborn provides a state of the art review on contemporary management of male lower urinary tract symptoms and BPH. Biography: Claus Roehrborn, MD is at the Harold C. Simmons Comprehensive Cancer Center. Dr. Roehrborn is the S.T. Harris Family Chair in Medical Science, in Honor of John D. McConnell, M.D. and the E.E. Fogelson and Greer Garson Fogelson Distinguished Chair in Urology. A worl...

Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn

In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors. Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in ea...

Genetic Evaluation of Hereditary Prostate Cancer - Sanjeev Kaul

(Length of Presentation: 27 min) Sanjeev Kaul discusses hereditary prostate cancer (HPC) and why HPC is important, which patients should be tested based on the NCCN guidelines and what tests are available. Also, presented is the process for clinic testing for HPC and the future directions in this field. Biography: Sanjeev Kaul, MD, M.CH, Comprehensive Urology, Associate Professor of Urology, Oakla...

Practice Changing Applications of Radiology and Nuclear Medicine in GU Malignancies- Phillip Koo

Phillip Koo presents practice changing applications of radiology and nuclear medicine in genitourinary malignancies in this lecture. He reviews the disruption in radiology specifically, imaging modalities, teleradiology, and artificial intelligence including the impact these have on patient care. Biography: Phillip J. Koo, MD , is the Division Chief of Diagnostic Imaging at the Banner MD Anderson...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.